Vor Biopharma (NASDAQ:VOR) Stock Lifted to “Strong-Buy” by Citigroup

Citigroup upgraded shares of Vor Biopharma (NASDAQ:VOR) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks reports.

Several other brokerages also recently weighed in on VOR. Wedbush upped their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Vor Biopharma Stock Performance

Shares of NASDAQ:VOR traded down $1.31 during mid-day trading on Thursday, hitting $18.03. 733,078 shares of the company traded hands, compared to its average volume of 1,316,671. The firm’s 50 day simple moving average is $21.57 and its 200 day simple moving average is $18.37. Vor Biopharma has a 52-week low of $6.50 and a 52-week high of $31.31.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). On average, sell-side analysts forecast that Vor Biopharma will post -2.56 earnings per share for the current fiscal year.

Institutional Trading of Vor Biopharma

Several institutional investors have recently added to or reduced their stakes in the stock. Braidwell LP boosted its stake in Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after acquiring an additional 106,330 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Vor Biopharma in the 1st quarter worth about $2,298,000. Bank of America Corp DE increased its position in shares of Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after purchasing an additional 112,496 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Vor Biopharma in the 2nd quarter valued at about $1,799,000. Finally, Simplify Asset Management Inc. acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at about $955,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.